Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP689983.RAySeciGEXnZP6KAdGEWLfvU1LlX4ZZSzoC8v33Zw_qSM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP689983.RAySeciGEXnZP6KAdGEWLfvU1LlX4ZZSzoC8v33Zw_qSM130_assertion type Assertion NP689983.RAySeciGEXnZP6KAdGEWLfvU1LlX4ZZSzoC8v33Zw_qSM130_head.
- NP689983.RAySeciGEXnZP6KAdGEWLfvU1LlX4ZZSzoC8v33Zw_qSM130_assertion description "[In this pilot study, we attempted to determine the optimal dosage regimens of esomeprazole for treatment of GERD with minimal influence of the CYP2C19 polymorphism through a study of the pharmacokinetics and pharmacodynamics of esomeprazole given at 3 different dosage regimens with the same total daily dose.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP689983.RAySeciGEXnZP6KAdGEWLfvU1LlX4ZZSzoC8v33Zw_qSM130_provenance.
- NP689983.RAySeciGEXnZP6KAdGEWLfvU1LlX4ZZSzoC8v33Zw_qSM130_assertion evidence source_evidence_literature NP689983.RAySeciGEXnZP6KAdGEWLfvU1LlX4ZZSzoC8v33Zw_qSM130_provenance.
- NP689983.RAySeciGEXnZP6KAdGEWLfvU1LlX4ZZSzoC8v33Zw_qSM130_assertion SIO_000772 18751689 NP689983.RAySeciGEXnZP6KAdGEWLfvU1LlX4ZZSzoC8v33Zw_qSM130_provenance.
- NP689983.RAySeciGEXnZP6KAdGEWLfvU1LlX4ZZSzoC8v33Zw_qSM130_assertion wasDerivedFrom befree-2016 NP689983.RAySeciGEXnZP6KAdGEWLfvU1LlX4ZZSzoC8v33Zw_qSM130_provenance.
- NP689983.RAySeciGEXnZP6KAdGEWLfvU1LlX4ZZSzoC8v33Zw_qSM130_assertion wasGeneratedBy ECO_0000203 NP689983.RAySeciGEXnZP6KAdGEWLfvU1LlX4ZZSzoC8v33Zw_qSM130_provenance.